Rare mutation, accessibility battles, and why we still fight. Today we talk with Ela. We learn about the 10 percent of CF patients who have rare mutations and cannot take gene modulators like Kalydeco or Trikafta. Our understanding of advocacy and accessibility gets revisited, and we connect with the clear reason why this fight is not done, and why fundraising must continue until CF stands for Cure Found.

To connect with Ela, visit the links below:

instagram: @ela_castillo

LinkdIn: www.linkedin.com/in/elacastillo/